MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients

Several discoveries have paved the way to personalise cancer medicine and a tremendous gain of knowledge in genomics and molecular mechanisms of cancer progression cumulated over the last years. Big stories in biology commonly start in a simple model system. No wonder microRNAs have been identified as regulators of embryonic development in the nematode Caenorhabditis elegans. From the first identification in worms to the first-in-man microRNA-based clinical trial in humans, almost 20 years passed. In this review we follow the story of understanding microRNA alterations in cancer, describe recent developments in the microRNA field and critically discuss their potential as diagnostic, prognostic and therapeutics factors in cancer medicine. We will explain the rationale behind the use of microRNAs in cancer diagnosis and prognosis prediction, but also discuss the limitations and pitfalls associated with this. Novel developments of combined microRNA/siRNA pharmacological approaches will be discussed and most recently data about MXR34, the first-tested microRNA drug will be described

MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer.

A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383-is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA

NaK Variable Conductance Heat Pipe for Radioisotope Stirling Systems

In a Stirling radioisotope power system, heat must continually be removed from the General Purpose Heat Source (GPHS) modules to maintain the modules and surrounding insulation at acceptable temperatures. The Stirling convertor normally provides most of this cooling. If the Stirling convertor stops in the current system, the insulation is designed to spoil, preventing damage to the GPHS, but also ending use of that convertor for the mission. An alkali-metal Variable Conductance Heat Pipe (VCHP) was designed to allow multiple stops and restarts of the Stirling convertor. In the design of the VCHP for the Advanced Stirling Radioisotope Generator, the VCHP reservoir temperature can vary between 40 and 120 C. While sodium, potassium, or cesium could be used as the working fluid, their melting temperatures are above the minimum reservoir temperature, allowing working fluid to freeze in the reservoir. In contrast, the melting point of NaK is -12 C, so NaK can't freeze in the reservoir. One potential problem with NaK as a working fluid is that previous tests with NaK heat pipes have shown that NaK heat pipes can develop temperature non-uniformities in the evaporator due to NaK's binary composition. A NaK heat pipe was fabricated to measure the temperature non-uniformities in a scale model of the VCHP for the Stirling Radioisotope system. The temperature profiles in the evaporator and condenser were measured as a function of operating temperature and power. The largest delta T across the condenser was 2S C. However, the condenser delta T decreased to 16 C for the 775 C vapor temperature at the highest heat flux applied, 7.21 W/ square cm. This decrease with increasing heat flux was caused by the increased mixing of the sodium and potassium in the vapor. This temperature differential is similar to the temperature variation in this ASRG heat transfer interface without a heat pipe, so NaK can be used as the VCHP working fluid

High Temperature Variable Conductance Heat Pipes for Radioisotope Stirling Systems

In a Stirling radioisotope system, heat must continually be removed from the GPHS modules, to maintain the GPHS modules and surrounding insulation at acceptable temperatures. Normally, the Stirling convertor provides this cooling. If the Stirling convertor stops in the current system, the insulation is designed to spoil, preventing damage to the GPHS, but also ending the mission. An alkali-metal Variable Conductance Heat Pipe (VCHP) is under development to allow multiple stops and restarts of the Stirling convertor. The status of the ongoing effort in developing this technology is presented in this paper. An earlier, preliminary design had a radiator outside the Advanced Stirling Radioisotope Generator (ASRG) casing, used NaK as the working fluid, and had the reservoir located on the cold side adapter flange. The revised design has an internal radiator inside the casing, with the reservoir embedded inside the insulation. A large set of advantages are offered by this new design. In addition to reducing the overall size and mass of the VCHP, simplicity, compactness and easiness in assembling the VCHP with the ASRG are significantly enhanced. Also, the permanently elevated temperatures of the entire VCHP allows the change of the working fluid from a binary compound (NaK) to single compound (Na). The latter, by its properties, allows higher performance and further mass reduction of the system. Preliminary design and analysis shows an acceptable peak temperature of the ASRG case of 140 C while the heat losses caused by the addition of the VCHP are 1.8 W